Company Description
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins.
The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1α, IL-1β and IL-18, as well as damage-associated molecular patterns.
In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast.
Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases.
The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates.
It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis.
The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2019 |
| IPO Date | Jun 24, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 150 |
| CEO | Markus Warmuth |
Contact Details
Address: 321 Harrison Avenue, Suite 900 Boston, Massachusetts 02118 United States | |
| Phone | 617 949 2643 |
| Website | monterosatx.com |
Stock Details
| Ticker Symbol | GLUE |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 1826457 |
| CUSIP Number | 61225M102 |
| ISIN Number | US61225M1027 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Philip Nickson J.D., Ph.D. | Chief Business and Legal Officer |
| Filip Janku M.D., Ph.D. | Chief Medical Officer |
| Matthew Bowen | Corporate Controller and Principal Accounting Officer |
| Jennifer Champoux | Chief Operating Officer |
| Magnus Walter DPHIL | Chief Technology Officer |
| Dr. John C. Castle Ph.D. | Chief Data and Information Officer |
| Dr. Sharon Townson Ph.D. | Chief Scientific Officer |
| Andrew Funderburk | Chief Investor Relations and Strategy Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 7, 2026 | 10-Q | Quarterly Report |
| May 7, 2026 | 8-K | Current Report |
| May 1, 2026 | 144 | Filing |
| Apr 29, 2026 | ARS | Filing |
| Apr 29, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 22, 2026 | SCHEDULE 13G/A | Filing |
| Apr 16, 2026 | 144 | Filing |
| Apr 14, 2026 | 144 | Filing |
| Apr 13, 2026 | 144 | Filing |